April 23, 2021 - Urgent: CDC Press Release: FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review
FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19
Massachusetts Providers May Resume Use
Dear Massachusetts Providers:
Following the CDC’s decision today to resume use of the Johnson & Johnson (Janssen) COVID-19 vaccine, all providers may resume administration of the J&J vaccine, effective immediately.
The pause was recommended after reports of six cases of a rare and severe type of blood clot in individuals following administration of the Janssen COVID-19 Vaccine. Following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Janssen (Johnson & Johnson) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.
Providers should review the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Fact Sheet for Recipients and Caregivers, which have been revised to include information about the risk of this rare type of blood clot, which has occurred in a very small number of people who have received the Janssen COVID-19 Vaccine.
More in the CDC news release: https://www.cdc.gov/media/releases/2021/fda-cdc-lift-vaccine-use.html.